Real-world Efficacy and Safety of Trastuzumab Deruxtecan in HER2-positive Metastatic Breast Cancer: A Multicenter Retrospective Study from Türkiye

Objective: Trastuzumab deruxtecan (T-DXd) is a novel human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugate that has demonstrated significant clinical activity in patients with HER2-positive metastatic breast cancer (mBC) in multiple pivotal trials. However, data regarding...

Descripció completa

Dades bibliogràfiques

Autors principals:	Harun MUĞLU, Erdem SÜNGER, Lamia ŞEKER CAN, Özgür HAN, Bünyamin GÜNEY, Jamshid HAMDARD, Burçin ÇAKAN DEMİREL, Özgür AÇIKGÖZ, Ömer Fatih ÖLMEZ, Mesut ŞEKER, Ahmet BİLİCİ
Format:	Artigo
Idioma:	Inglês
Publicat:	Turkish Society of Oncology 2026-04-01
Col·lecció:	Journal of Oncological Sciences
Matèries:	trastuzumab deruxtecan her2-positive breast cancer metastatic breast cancer real-world evidence antibody-drug conjugate interstitial lung disease progression-free survival
Accés en línia:	https://www.journalofoncology.org/articles/real-world-efficacy-and-safety-of-trastuzumab-deruxtecan-in-her2-positive-metastatic-breast-cancer-a-multicenter-retrospective-study-from-turkiye/doi/jos.galenos.2026.2026-1-1
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!